

Shrabanti Chowdhury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1643347/publications.pdf>

Version: 2024-02-01

25
papers

1,625
citations

1040056

9
h-index

794594

19
g-index

31
all docs

31
docs citations

31
times ranked

2089
citing authors

#	ARTICLE	IF	CITATIONS
1	New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes. <i>Biostatistics</i> , 2022, 23, 136-156.	1.5	4
2	Differential expression of single-cell RNA-seq data using Tweedie models. <i>Statistics in Medicine</i> , 2022, 41, 3492-3510.	1.6	11
3	Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma. <i>Analytical Chemistry</i> , 2022, 94, 9540-9547.	6.5	11
4	A model-free approach for testing association. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2021, 70, 511-531.	1.0	0
5	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 361-379.e16.	16.8	189
6	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , 2021, 39, 509-528.e20.	16.8	327
7	Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. <i>Clinical Chemistry</i> , 2021, 67, 1008-1018.	3.2	29
8	Abstract 1426: Multiomic analysis identifies CPT1A and fatty acid oxidation as a potential therapeutic target in platinum-refractory high grade serous ovarian cancer. , 2021, , .		0
9	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. <i>Cell Reports Medicine</i> , 2021, 2, 100471.	6.5	26
10	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	28.9	177
11	Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020, 180, 729-748.e26.	28.9	296
12	A-ComVar: A Flexible Extension of Common Variance Designs. <i>Journal of Statistical Theory and Practice</i> , 2020, 14, 1.	0.5	0
13	TBIO-19. INTEGRATED GENOMIC, PROTEOMIC AND PHOSPHOPROTEOMIC ANALYSIS OF SEVEN TYPES OF PEDIATRIC BRAIN CANCER. <i>Neuro-Oncology</i> , 2020, 22, iii470-iii470.	1.2	1
14	Abstract 445: Integrated proteogenomic characterization across seven histological types of pediatric brain tumors. , 2020, , .		0
15	Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers. , 2020, , .		0
16	Bayesian Approach for Assessing Non-Inferiority in Three-Arm Trials for Risk Ratio and Odds Ratio. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 34-43.	0.8	2
17	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019, 179, 964-983.e31.	28.9	430
18	Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions. <i>AIDS Patient Care and STDs</i> , 2019, 33, 388-398.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Approaches for testing noninferiority in two-arm trials for risk ratio and odds ratio. Journal of Biopharmaceutical Statistics, 2019, 29, 425-445.	0.8	4
20	Group regularization for zero-inflated poisson regression models with an application to insurance ratemaking. Journal of Applied Statistics, 2019, 46, 1567-1581.	1.3	9
21	Non-inferiority testing for risk ratio, odds ratio and number needed to treat in three-arm trial. Computational Statistics and Data Analysis, 2019, 132, 70-83.	1.2	8
22	A Note on the Adaptive LASSO for Zero-Inflated Poisson Regression. Journal of Probability and Statistics, 2018, 2018, 1-9.	0.7	7
23	Group regularization for zero-inflated negative binomial regression models with an application to health care demand in Germany. Statistics in Medicine, 2018, 37, 3012-3026.	1.6	8
24	CV, ECV, and Robust CV designs for replications under a class of linear models in factorial experiments. Journal of Statistical Planning and Inference, 2017, 188, 1-7.	0.6	3
25	A more powerful test for three-arm non-inferiority via risk difference: Frequentist and Bayesian approaches. Journal of Applied Statistics, 0, , 1-23.	1.3	0